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Particulate air pollution has been implicated
in the incidence and severity of respiratory
disease. Acute effects ofparticles on respira-
tory symptoms have been demonstrated in
panel studies (1-A, and decreases in lung
function have been observed (1,2,4-8).
Asthmatic patients have reported increasing
theirbeta-agonist use in association with par-
ticulate air pollution (2,4,7,8). These acute
effects of particulate matter particles of 10
pm or less in aerodynamic diameter (PM1)
have been observed in children with respira-
tory symptoms (1,4,5), in children without
respiratory symptoms (1), and in asthmatic
patients (2,5,4, but some studies have failed
to show consistent associations between par-
ticulate air pollution and lung function
(9-11) or any respiratory symptoms (9,10)
during particulate air pollution episodes.
These differences in response may be due to
differences in the panel characteristics or in
the air pollution exposures. Subjects with
preexisting chronic respiratory disease are
considered to be subgroups of the popula-
tion that are sensitive for health effects.
Under conditions in which pollutant values
are near or below the recommended guide-
lines, symptomatic children appeared to be
the most sensitive subgroup (1,4, whereas
studies of asthmatic patients have failed to
showconsistent associations (9-14.
These latter results were unexpected
because most subjects with asthma have
hyperreactive airways that respond to non-
specific external stimuli (13). Howevi
experimental studies on young adults wi
mild asthma have shown that routinely us
asthma medications such as theophylli
and beta-agonist were able to attenuate
reverse the effects ofsulfur dioxide (SO2)
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Materials and Methods
D Studyarea. Sokolovis acityofapproximately
60,000 inhabitants, located in a hilly region
in the northwest of the Czech Republic. A
powerplantlocated 5 km westofthecityand
1'' small-scale industry are the primary sources
I ofwinter air pollution. Glass and china man-
i ufacturing plants are scattered within 20 km
ofSokolov. Brown coal (lignite) is usedwide-
ly in both power production and domestic
if heating. The high sulfur and ash content of
the coal produces high SO2 and particulate
airpollution in thewinter.
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cough, bronchitis, excessive phlegm pro-
duction, or spastic bronchitis. Written
informed consent was obtained from par-
ents before their children were enrolled in
the study. Data were collected between
January 1991 and June 1992. The analyses
presented here are restricted to the winter
of 1991-1992 (15 November-4 February
1992) to allow the analysis of inidividual
time series with generalized linear models.
Eighty-two children aged 6-14 years old at
the end of 1991 participated during the
period ofanalysis.
Lung function was assessed daily by
measuring peak expiratory flow (PEF) rates
with a Mini Wright Peak Flow meter
(range 60-800 liter/min). PEF measure-
ments during the first 2 weeks were discard-
ed to eliminate learning effects. A detailed
description ofthe study design is given else-
where (8,19). Participants recorded the
highest of these PEF measurements before
taking medication in the morning and in
the evening. Ifthe subject took medication,
a second measurement was made 10 min
after the dose. Reports ofcough during the
night before, cough during the day, dysp-
nea at rest, dyspnea at night, dyspnea on
exertion, runny nose, phlegm, fever, school
absence, and time spent outdoors were col-
lected in the diary. Use ofasthma medica-
tion (including time, amount, and name of
drug) was also recorded. Prescriptions con-
taining theophylline were converted to mil-
ligram of active drug. Beta-agonist use was
coded as number ofpuffs.
Airpollution data. Pollutants [SO2,
nitrogen dioxide (NO2), and total suspend-
edparticles (TSP)] and meteorological vari-
ables (temperature, relative humidity, baro-
metric pressure, wind speed, and wind
direction) were measured at one central
site. Acid aerosols were sampledwith a size-
selective impactor and ammonia denuder.
Concentrations ofsulfates were determined
by ion chromatography, and acidity was
determined by pH measurement of 24-hr
samples of particles with an aerodynamic
diameter less than 2.5 pm. PMIO was mea-
sured at the same location and on the same
schedule. Daily measurements ofPM1O and
acid aerosols were only available during the
winter of 1991-1992. A detailed descrip-
tion of the exposure assessment is given
elsewhere (20,21).
Episodes of elevated air pollution last-
ing longer than 7 days occurred repeatedly
during the winter of 1991-1992 in
Sokolov (8). Air pollution was dominated
by SO2, with a mean concentration of 100
pg/m3 (maximum: 383 1pg/m3) during the
period of analysis. TSP had a mean con-
centration of 83 pg/m3 (maximum: 325
1pg/m3) and PM1O a mean concentration of
55 pg/m3 (maximum: 171 pg/m3). Con-
centrations ofsulfate fine particles averaged
8.8 pg/m3 (maximum: 23.8 pg/m3).
Particle strong acidity (PSA) was on aver-
age below the detection limit (22), despite
high SO2 concentrations. The highest air
pollution concentrations were observed
between the middle of November 1991
and the middle ofDecember 1991. During
the following 5 weeks, air pollution was
much lower in Sokolov. At the end of
January 1992, SO2 concentrations stayed
above 200 pg/m3 for 12 days. On the first
day of this air pollution episode (25
January 1992), the highest PSA concentra-
tion (4.8 pg/m3) was detected. This value
was confirmed by an independent measure-
ment by a second sampler (20). The con-
centrations of SO2 and particle measure-
ments were highly correlated; for example,
sulfate (SO4) concentrations were highly
correlated with SO2 (r= 0.79) andPM1O (r
= 0.80). PMIO was strongly correlated with
TSP (r = 0.90) and SO2 (r = 0.75). No
data on ozone concentrations were avail-
able for Sokolov during the winter of
1991-1992 because of low levels. These
analyses are therefore restricted to the
effects of particulate and sulfur pollution.
To simplify the presentation in the follow-
ing section, results are presented only for
SO4 as a general indicator of particulate
and sulfur pollution. SO4 was previously
shown to be the air pollution indicator
most strongly and consistently associated
with PEF in the larger panel study (6,8).
Statistical analysis. Previous analyses of
panels of asthmatic subjects have used
time-series methods to evaluate the associa-
tion between the mean day-specific health
outcomes and air pollution (6,8). In this
study, the impact ofmedication use on sub-
ject-specific time series was analyzed with
generalized linear models (23,24). Models
for binary and normally distributed data
were estimated with control for a linear
trend, 24-hr mean temperature, and week-
end (versus weekday). To control for viral
infections that mayhave coincidedwith high
exposures to air pollution at the end of
January 1992, additional analyses adjusted
for the mean prevalence of fever in the
cohort. A detailed analysis ofpossible con-
founding ofthe association between respira-
tory health and air pollution by viral infec-
tions has been published elsewhere (8).
Missing observations were assumed to be
missing completely at random and were
omitted. Because repeated measurements
were taken on each individual, a
variance-covariance structure that took into
account that the error-term was associated
with the outcome measured on the previous
day was considered. Analyses were restricted
to the 82 patients who contributed more
than 21 observations (average: 76.8 observa-
tions) during the period ofanalysis; 95%
confidence intervals were calculated on the
basis of robust standard errors. Previous
analyses suggested that the strongest associa-
tions between health outcomes and airpollu-
tion were attributable to the concentrations
ofsulfate fine partides (8). SO4 was chosen
to present analyses with regard to medication
use because it measured the partide fraction
attributable to SO2, the major air pollutant
ofthe area. Same-day and 5-day mean (cur-
rent plus 4 previous days) SO4 was used to
compare immediate and delayed impact of
air pollutants. In the case of missing expo-
sure data, the mean ofthe available measure-
ments was taken. Cough induded reporting
ofcough during the day or cough during the
night before. Dyspnea included dyspnea at
rest, on exertion, or at night. Beta-agonist
and theophylline use were summarized in a
binary variable, which was 1 iftheophylline
or beta-agonist use was recorded.
Associations between medication use and
symptoms were evaluated by indusion ofan
indicator for medication in the logistic mod-
els with control for a linear trend, 24-hr
mean temperature, weekend (versus week-
day), and 5-daymean ofSO4.
Results
The cohort of82 children was divided into
those who did (n = 51) or did not (n= 31)
use asthma medication during the period
15 November 1991-14 February 1992
(Table 1). Children who took medication
were reported to have a diagnosis ofasthma
more frequently, but the prevalence of
bronchitic symptoms was similar. The
medicated children were slightly younger,
had lower mean PEF, and reported a high-
er prevalence of symptoms than nonmed-
icated children. The prevalence of cough,
dyspnea, and phlegm was more than three
times higher among medicated children,
and they reported fever more frequently
and were absent from school more often
during the period ofanalysis than nonmed-
icated children.
Exacerbation of asthma in 22 children
was treated with theophylline only. One
child used beta-agonist alone, and eight
children used both types of medication.
Two ofthe children were receiving continu-
ous therapy, one with theophylline only
and one with theophylline and beta-agonist
(Fig. 1). All other children took asthma
medication infrequently as needed. There
were shortages of beta-agonist during the
whole study period, which might explain
the low prevalence of beta-agonist use
(rather than a preference for a different
approach to asthma therapy). Cortisonewas
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not prescribed for any ofthe children dur- ods but not during the analysis period. The
ing the study period. None of the children medicated children (n = 31) provided 2,422
used aerosol medication with combinations person-days out of the total 6,294 person-
ofbeta-agonist and cortisone. The nonmed- days recorded during the 3-month period.
icated children included 26 subjects who Theophylline was used on 588 person-days
reported medication use during other peri- and aerosol sprays on only 111 person-days.
Table 1. Characteristics of patients from Sokolov
Medication use
All None During period of analysis8
Number of patients 82 51 31
Age (mean years) 9.8 9.9 9.5
Gender 50 m/32f 30 m/21 f 20 m/1If
Asthma 69 (86%) 41 (80%) 28(93%)
Bronchitic symptoms 69(86%) 42(82%) 27 (87%)
Peak expiratoryflow(mean) 296 I/min 307 I/min 278 I/min
Symptom on more than 20% ofdays
Any 44(54%) 17 (33%) 27 (87%)
Cough 34(41%) 10 (20%) 24 (77%)
Dyspnea 12 (15%) 1(2%) 11(36%)
Phlegm 11(13%) 3(6%) 8(26%)
Runny nose 28 (34%) 13(25%) 15(48%)
School absence on morethan 20% ofdays 14(17%) 5(10%) 9 (27%)
Fever on more than 5% ofdays 9(11%) 4(8%) 5(16%)
No symptom during whole period 0 0 0
a15 November 1991-14 February 1992.
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Table 2. Comparison of effect estimates,9for concurrentS04 concentrations expressed for an increase of
8pg/iM3
Medication use
All None During period ofanalysisb
Change in PEF(95% confidence intervals)
PEF[I/min] -0.48 (-1.59,0.63) 0.02 (-1.46,1.49) -1.21 (-3.28,0.85)
Odds ratio (95% confidence intervals)
Anysymptom 1.01 (0.97,1.05) 1.07 (0.98,1.18) 0.92(0.83,1.02)
Cough 1.04(0.92,1.18) 1.08 (0.96,1.23) 1.01 (0.92,1.12)
Dyspnea 1.03(0.88,1.20) 1.05 (0.77,1.44) 0.99(0.83,1.17)
Phlegm 1.04(0.92,1.18) 1.11 (0.92,1.34) 0.97 (0.87,1.09)
Runny nose 1.07 (1.00,1.14) 1.13(1.03,1.24) 1.01 (0.93,1.10)
School absence 0.99(0.91,1.07) 0.92(0.79,1.08) 1.07 (0.96,1.19)
Fever 1.35 (0.92,1.97) 1.23(0.78,1.94) 1.52(0.95,2.44)
beta-Agonist use 1.07 (0.91,1.25) - 1.08(0.88,1.32)
Theophylline use 1.01 (0.95,1.08) - 1.03(0.89,1.18)
PEF, peak expiratoryflow.
8Adjusted fortemperature, a lineartrend, and weekend (vs. weekday).
b15 November 1991-14 February 1992.
Separate analyses for medicated and
nonmedicated children were conducted to
evaluate differences in response to particu-
late air pollution. Table 2 presents the
results ofthe multivariate regression analy-
ses of same-day SO4 concentrations on
lung function, symptoms, and medication
use. All analyses adjusted for a linear trend,
24-hr mean temperature, and an indicator
for weekend (versus weekday). The regres-
sion coefficients or odds ratios are given for
an increase of one interquartile range of
SO4 (8 pg/m3). Exposure to SO4 on the
same day was not strongly associated with
decreased lung function, increased preva-
lence ofrespiratory symptoms, or increased
absence from school in the nonmedicated
or medicated children or in the total
cohort. A decrease in PEF was observed
only for the medicated children. The esti-
mates for SO4 were slightly larger for respi-
ratory symptoms in nonmedicated children
than in medicated children, but the associ-
ation was not statistically significant.
Evidence for a possible association between
fever and same-daySO4 concentrations was
found in both subgroups. The prevalence
of beta-agonist use among the medicated
children was not associated with concur-
rent exposure to SO4.
Table 3 presents the results ofthe mul-
tivariate regression analyses, with a 5-day
mean to quantify cumulative effects ofSO4
concentration. All effect estimates were
multiplied by one interquartile range ofthe
5-day mean ofSO4 (6.5 pg/m3) and can be
compared directly with those in Table 2.
The responses to cumulative exposure to
SO4 differed between medicated and non-
medicated children. The decrease in PEF
associated with increased levels of a 5-day
mean ofSO4 was four times larger in med-
icated children than nonmedicated chil-
dren. It accounted nearly entirely for the
association observed in the total cohort.
While an odds ratio larger than 1 was
observed for cough in both subgroups, an
increase in the prevalence of dyspnea in
association with SO4 was observed only in
the nonmedicated children. The association
between a 5-day mean of SO4 and the
prevalence offever was most pronounced in
the medicated subgroup, for whom an
increase in runny nose was observed as well.
There was a statistically significant associa-
tion between beta-agonist use and a 5-day
mean ofSO4. Large standard errors associ-
ated with the effect estimates for the non-
medicated children, despite the fact that 51
panelists belonged to the subgroup, indicat-
ed that the group included a sample with
large variability in their responses to partic-
ulate air pollution. Halfofthe nonmedicat-
ed children took asthma medication in the
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Table 3. Comparison of effect estimatesa for a 5-day mean of S04 concentration expressed for an
increase of6.5 pg/m3
Medication use
All None During period of analysisb
Change in PEF (95% confidence intervals)
PEF[I/min] -3.25 (-5.50-1.00) -1.35 (-3.69,0.99) -5.62(-9.93,-1.30)
Odds ratio (95% confidence intervals)
Any symptom 1.07 (0.95,1.20) 1.10(0.92,1.31) 1.05 (0.86,1.29)
Cough 1.19(1.05,1.34) 1.27 (1.01,1.60) 1.16(1.00,1.34)
Dyspnea 1.09 (0.91,1.31) 1.18 (0.98,1.41) 1.04(0.83,1.29)
Phlegm 1.01 (0.86,1.19) 1.18 (0.80,1.76) 0.88 (0.70,1.12)
Runny nose 1.16 (0.99,1.36) 1.16 (0.94,1.44) 1.17 (0.94,1.47)
School absence 1.05 (0.87,1.27) 1.06(0.77,1.46) 1.05 (0.85,1.31)
Fever 1.71 (1.11,2.64) 1.36(0.82,2.26) 2.26(1.11,4.61)
beta-Agonist use 1.45 (1.09,1.92) - 1.46(1.08,1.98)
Theophylline use 0.99(0.80,1.22) - 0.99 (0.77,1.26)
PEF, peak expiratoryflow.
aAdjusted fortemperature, a lineartrend, and weekend (vs. weekday).
b15 November 1991-14 February 1992.
Table 5. Qualitative summary ofthe group characteristics and observed effects
Nonmedicated Medicated
children (n= 51) children (n= 31)
Grade of asthma Slight Moderate
Symptom prevalence Low High
Medication use None If needed
Hypothesized reactivityto external stimuli Low Moderate
Observed associations between health outcomes
and S04 concentrations
Peak expiratoryflow None Decrease
Respiratory symptoms Increase in dyspnea Increase in cough
Medication use Increase
year preceding the analyses, but not during
this specific study period. The associations
observed between symptoms and a 5-day
mean of SO4 were largely attributable to
this subgroup.
Treatmentwith medication as an indica-
tor for either theophylline or beta-agonist
use did not confound the association
between the health outcomes and the expo-
sure to SO4 as shown in Table 4 for the 5-
day mean ofS04. Increased symptoms and
decreased PEF were strongly associated with
increased medication use. All symptoms
except runny nose were associated with
increased medication use. The children
appeared to adjust their medication use
according to their perception oftheir health.
The strongest associations were found for
dyspnea at night and at rest, which were
symptoms indicating an exacerbation of
asthma. However, adjustment for medica-
tion use did not modify the associations
with the 5-day mean S04 concentration
(Table 4 comparedwith Table 3 results).
Viral infections at the end ofJanuary
1992 may have coincided with an episode
of particulate air pollution and potentially
confounded the association between health
outcomes and SO4 exposures (8). Addi-
tional analyses adjusting for the prevalence
of fever in the sample were conducted in
order to assess possible confounding. The
association between the PEF and SO4 was
not altered in these additional analyses
(Fig. 2A). However, associations between
phlegm/runny nose and SO4 concentra-
tions were reduced in the nonmedicated
children but not in the medicated children
after adjustment for fever (Fig. 2B). The
effect estimates for the association between
health outcomes and medication use were
not confounded by the prevalence offever.
Discussion
Previous analyses showed decreased PEF
rates and increased prevalence of respirato-
ry symptoms and beta-agonist use in asso-
ciation with increased 5-day means of sul-
fate fine particle concentrations in children
with mild asthma from Sokolov, the Czech
Republic (6,8). Concentrations of sulfate
fine particles may serve as an indicator pol-
lutant in an atmosphere with a complex
mixture of air pollutants dominated by
high SO2, moderate levels of particulate
matter, and low acidity (8,20,21).
An analysis of these same data for a 3-
month period during the winter of
1991-1992 stratified by medication use,
suggested that nonmedicated children (51
panelists) differed substantially from chil-
dren who took medication (31 panelists) in
Table 4. Effect estimatesa for 5-day mean of S04
concentrations expressed for an increase of 6.5
pg/M3 and any medication use estimated jointly in
one model for all children
S04 Medication use
Change in PEF(95% confidence intervals)
PEF[I/min] -3.19(-5.40,-0.98) -14.9(-22.3,7.50)
Odds ratio(95% confidence intervals)
Anysymptom 1.08(0.95,1.23) 4.31 (2.60,7.13)
Cough 1.21 (1.08,1.36) 3.67(2.05,6.56)
Dyspnea 1.08(0.87,1.33) 12.30(5.43,27.9)
Phlegm 1.00(0.81,1.24) 2.39(1.32,4.32)
Runnynose 1.16(0.99,1.36) 1.20(0.91,1.57)
School absence 1.05(0.87,1.27) 2.36(1.40,3.98)
Fever 1.64(1.05,2.54) 2.48(1.05,5.86)
PEF, peak expiratoryflow.
aAdjusted for temperature, a linear trend, and
weekend (vs.weekday).
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their general characteristics and their
responses to particulate airpollution (Table
5). The children treated with asthma med-
ication had more severe asthma as indicat-
ed by a high prevalence of respiratory
symptoms, which presumably led to more
frequent absence from school. Although
the medicated children increased their
beta-agonist use in association with an
increased 5-day mean concentration of
so4, the strongest decrease in PEF was
observed in this subgroup. Despite a higher
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prevalence of respiratory symptoms among
medicated children, effect estimates quanti-
fying the association between SO4 and res-
piratory symptoms appeared to be larger
for nonmedicated children. Although
results are presented only for SO4, similar
results were found for SO2, TSP, PM10,
and particle acidity as in previous analyses
(8). Only weak associations were observed
with TSP and PMIO and health outcomes,
even after adjustment for medication use.
Chamber studies have indicated that
medication use attenuates or reverses the
effects ofair pollutants on health outcomes
in asthmatic volunteers (14-16). Therefore,
medication use can be a confounder, as has
been suggested by Silverman et al. (17). No
confounding by medication use was
observed in this study, since controlling for
concurrent medication use did not alter the
effect estimates for particulate air pollution.
The children in Sokolov received theo-
phylline as their basic medication, with
beta-agonist treatment as needed. They
kept asthma medication at home for emer-
gencies, which resulted in variation of the
doses in a range determined by a recom-
mendation from their physician. Therefore,
the variation in doses of medication may
reflect the impact ofother external stresses.
Medication use was found to be strongly
associated with decreases in PEF and the
presence of respiratory symptoms. The
intensive monitoring of the incidence of
symptoms and changes in lung function
was likely to influence medication use.
Therefore, increased symptom prevalence
and decreased lung function measurements
during particulate air pollution episodes
may be responsible for the observed increas-
es in beta-agonist use. Although the chil-
dren adjusted the medication use according
to their symptoms, they did not suppress
the adverse effects ofSO4 on their PEF and
cough, possibly due to inadequate supplies
of medication. Evidence for a protective
effect ofmedication use was found for dys-
pnea, which increased in association with
exposure to SO4 only in nonmedicated
children. Dyspnea was the strongest predic-
tor for medication use. Thus, this study
suggests that medication use diminishes the
effects of ambient particulate air pollution
on asthmatics. However, it should be
stressed that under Western treatment regi-
mens (18) and with adequate availability of
medication, the medicated children may
not have shown associations between SO4
and health outcomes.
The associations between health out-
comes and elevated levels of SO4 may be
confounded by coinciding viral infections
(25). In a longitudinal study of children
who reported wheezing or persistent
cough, exacerbation of symptoms and
severe decreases in PEF were, in 80% of
the cases, associated with the presence of
viruses detected by polymerase chain reac-
tion (26). In order to eliminate this possi-
bility, regression results adjusted for the
prevalence of fever in the sample are pre-
sented here. The association of decreased
PEF and increased SO4 were not con-
founded by viral infections. However, the
effect estimates calculated for SO4 and
symptoms were attenuated for nonmedicat-
ed children. Of all groups, the actively
medicated children had the highest preva-
lence of fever; nonetheless, the observed
associations between cough and a 5-day
mean of SO4 were not altered. Although
the impact of viral infection coinciding
with an episode ofparticulate air pollution
cannot be ruled out entirely (8), the possi-
bility ofconfounding does not weaken the
role ofmedication as an effect modifier.
Pope et al. (2) compared a school-based
sample of children with respiratory symp-
toms to a panel ofasthma patients. Asthma
patients showed polynomially distributed
lag structures forPMI0 and PEF, which sug-
gests that a 5-day moving average would
show bigger effect estimates than concurrent
exposure to PM 0. The school-based sample
showed an immediate effect of particulate
air pollution on PEF and symptoms, but the
asthma panel did not. One possible explana-
tion for these differences is beta-agonist use,
which increased in the asthma panel in asso-
ciation with increasingPM10.
The observed health effects and their
potential modification by medication use
were associated with air pollution originat-
ing from the burning of lignite. Two epi-
demiological studies [from Pope et al.(2)
and the results presented here] suggest that
effect estimates for particulate air pollution
on symptoms may be underestimated when
medication is used byasthmatic patients.
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The 42nd Institute inWater Pollution Control
Leo Engineering Building
Manhattan College
June 1997
Two courses will be offered
Modeling ofTransport, Fate, and Bioaccumulation ofToxic Substances
June 2-June 6, 1997
Treatment of Municipal, Hazardous,andToxicWastewaters
June 2-June 6, 1997
Tuition for each course is $1,200.00, which includes a set of notes for each attendee.
Preregistration for enrollment is required.
Who should attend?
These continuing engineering programs are designed for practicing engineers and scientists in industry, consulting
engineering, research organizations, academic institutions, and city, state, and federal agencies.
Why should you attend?
These week-long courses will provide important information and updates in the rapidly changing field ofwater pollution
control for young engineers and seasoned professionals. The courses are set in a classroom atmosphere to promote
dialogue between participants and lecturer.
For a brochure and further information, contact
Lucia Chiocchio, Program Coordinator
Environmental Engineering Department
Manhattan College
Riverdale, New York 10471
Telephone: (718) 862-7277. Fax: (718) 862-8018.
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